澳洋健康收盘下跌1.80%，滚动市盈率117.88倍，总市值33.39亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a significant decline in revenue and net profit in the first quarter of 2025 compared to the previous year [1][2] - Aoyang Health's closing stock price on August 22 was 4.36 yuan, down 1.80%, with a rolling PE ratio of 117.88 times, and a total market capitalization of 3.339 billion yuan [1] - The average PE ratio for the healthcare service industry is 49.39 times, with a median of 62.33 times, placing Aoyang Health at the 39th position within the industry [1][2] Group 2 - For the first quarter of 2025, Aoyang Health reported an operating income of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% year-on-year, with a sales gross margin of 15.09% [2] - As of March 31, 2025, Aoyang Health had 53,714 shareholders, a decrease of 3,624 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1]